RCT | Cabozantinib plus atezolizumab vs. sorafenib for advanced hepatocellular carcinoma.

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology

Invited Commentary: Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy – The Lancet Oncology (free registration required)

Commentary on Twitter

In the phase III COSMIC-312 trial in 837 pts with advanced-stage HCC, mPFS was 6.8 vs 4.2 months (HR 0.63; P=.0012) & mOS was 15.4 vs 15.5 months (HR 0.90; P=.44) with cabozantinib+atezolizumab vs sorafenib; mPFS with cabozantinib alone was 5.8 months: https://t.co/eiZEqSxLAr

— NatureRevClinOncol (@NatRevClinOncol) July 6, 2022